232 related articles for article (PubMed ID: 33782950)
21. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
22. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
23. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
24. Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia.
Frikha R; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2022 Dec; 28(8):1826-1831. PubMed ID: 34846219
[TBL] [Abstract][Full Text] [Related]
25. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
27. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
Lübking A; Dreimane A; Sandin F; Isaksson C; Märkevärn B; Brune M; Ljungman P; Lenhoff S; Stenke L; Höglund M; Richter J; Olsson-Strömberg U
Bone Marrow Transplant; 2019 Nov; 54(11):1764-1774. PubMed ID: 30962502
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Chamoun K; Kantarjian H; Atallah R; Gonzalez GN; Issa GC; Rios MB; Garcia-Manero G; Borthakur G; Ravandi F; Jain N; Daver N; Konopleva M; DiNardo CD; Kadia T; Pemmaraju N; Jabbour E; Cortes J
J Hematol Oncol; 2019 Jan; 12(1):1. PubMed ID: 30606227
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
32. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
33. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Rea D; Mahon FX
Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of TKI therapy and 'functional' cure for CML.
Mahon FX
Best Pract Res Clin Haematol; 2016 Sep; 29(3):308-313. PubMed ID: 27839571
[TBL] [Abstract][Full Text] [Related]
35. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC; Pereira A; Pastor-Galán I; Alvarez-Larrán A; Savchuk A; Puerta JM; Sánchez-Pina JM; Collado R; Díaz-González A; Angona A; Sagüés M; García-Gutiérrez V; Boqué C; Osorio S; Vallansot R; Palomera L; Mendizábal A; Casado LF; Pérez-Encinas M; Pérez-López R; Ferrer-Marín F; Sánchez-Guijo F; García C; Heras NL; López-Lorenzo JL; Cervantes F; Steegmann JL;
Blood Cancer J; 2018 Dec; 8(10):91. PubMed ID: 30504932
[TBL] [Abstract][Full Text] [Related]
37. Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Söderlund S; Persson I; Ilander M; Guilhot J; Hjorth-Hansen H; Koskenvesa P; Richter J; Saussele S; Mustjoki S; Olsson-Strömberg U
Leuk Res; 2020 Mar; 90():106310. PubMed ID: 32058176
[TBL] [Abstract][Full Text] [Related]
38. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
Yamaguchi H; Takezako N; Ohashi K; Oba K; Kumagai T; Kozai Y; Wakita H; Yamamoto K; Fujita A; Igarashi T; Yoshida C; Ohyashiki K; Okamoto S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Hematol; 2020 Mar; 111(3):401-408. PubMed ID: 31894533
[TBL] [Abstract][Full Text] [Related]
39. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
Cerveira N; Bizarro S; Teixeira MR; Mariz JM
Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
[TBL] [Abstract][Full Text] [Related]
40. [A Retrospective Analysis of TKI Discontinuation in Patients with CML].
Zhao XL; Hong M; Qiao C; Sun Q; Zhu H; Wang S; Li JY; Qian SX; Zhu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1746-1751. PubMed ID: 34893104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
